Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials

© Springer Nature Switzerland AG 2020..

The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50-1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80-5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76-3.50]) or 14-day viral (OR 5.37 [95% CI 0.35-83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases.

Media Type:

Electronic Article

Year of Publication:

2020

Contained In:

SN comprehensive clinical medicine - (15.07.2020), p. 1-12

Language:

English

Contributors:

Siordia, Juan A
Bernaba, Michael
Yoshino, Kenji
Ulhaque, Abid
Kumar, Sooraj
Bernaba, Mario
Bergin, Edward

Links:

Volltext

Keywords:

Arbidol
COVID-19
Coronavirus
Dexamethasone
Favipiravir
Heparin
Hydroxychloroquine
Journal Article
Lopinavir/ritonavir
Remdesivir
Review
SARS-CoV2
Tocilizumab
Treatment
Trials

Notes:

Date Revised 28.09.2020

published: Print-Electronic

Citation Status Publisher

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1007/s42399-020-00399-6

PMID:

32838169

PPN (Catalogue-ID):

NLM315057300